Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 195

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

Megan Bowers & Mikayla Hellwich: MDMA History, Harm Reduction, and the Problem With Prohibition

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic...

Numinus Completes First MDMA Administration in PTSD Trial Sponsored by MAPS

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial...

Albert Labs Files US Provisional Patent Application and Proves Out Consistent...

PT305 – Emma Farrell – Plant Spirits, Entities, and Remembering Lost...

MindMed Reports Full Year 2021 Financial Results and Business Highlights

MindMed Announces Transition of CFO

Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study

Nova Mentis Begins Enrollment in North American Autism Study

Psychedelic Bulletin: COMPASS Partners with NHS Trust to Launch Centre; Disturbing...

Load more

EDITOR PICKS

Weekly Psychedelic Policy Briefing – August 9, 2026

Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?

The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©